KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EBIT (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed EBIT for 18 consecutive years, with $642.9 million as the latest value for Q1 2026.

  • For Q1 2026, EBIT rose 8.65% year-over-year to $642.9 million; the TTM value through Mar 2026 reached $3.6 billion, down 5.27%, while the annual FY2025 figure was $3.6 billion, 10.34% down from the prior year.
  • EBIT hit $642.9 million in Q1 2026 for Regeneron Pharmaceuticals, down from $879.9 million in the prior quarter.
  • Across five years, EBIT topped out at $1.3 billion in Q1 2022 and bottomed at $591.7 million in Q1 2025.
  • Average EBIT over 5 years is $999.9 million, with a median of $1.0 billion recorded in 2025.
  • On a YoY basis, EBIT climbed as much as 13.1% in 2022 and fell as far as 66.84% in 2022.
  • Regeneron Pharmaceuticals' EBIT stood at $1.1 billion in 2022, then decreased by 15.16% to $972.9 million in 2023, then grew by 1.78% to $990.2 million in 2024, then dropped by 11.14% to $879.9 million in 2025, then dropped by 26.93% to $642.9 million in 2026.
  • According to Business Quant data, EBIT over the past three periods came in at $642.9 million, $879.9 million, and $1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.